Trade 3SBio Inc. - 1530 CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.1
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investmentHK$1,000.00Overnight funding adjustmentCharges from full value of position-0.01829 %(-HK$3.66)Trade size with leverage ~ HK$20,000.00Money from leverage ~ $HK$19,000.00Go to platform: -0.01829%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investmentHK$1,000.00Overnight funding adjustmentCharges from full value of position-0.00362 %(-HK$0.72)Trade size with leverage ~ HK$20,000.00Money from leverage ~ $HK$19,000.00Go to platform: -0.00362%
• Overnight funding adjustment time: 22:00 (UTC)
• Currency: HKD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: Hong Kong
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: HK$1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.01829 %
  (-HK$3.66)

• Margin. Your investment: HK$1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00362 %
  (-HK$0.72)

Key Stats

• Prev. Close: 13.6
• Open: 13.55
• 1-Year Change: -55.93%
• Day's Range: 13.55 - 13.95

Trade 3SBio Inc. - 1530

3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals. The company's primary products include TPIAO, a recombinant human thrombopoietin for thrombocytopenia; Yisaipu, a tumour necrosis factor for treating rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and EPIAO, a recombinant human erythropoietin for the treatment of anemia associated with chronic kidney disease (CKD), chemotherapy-induced anemia, and reduction of allogeneic blood transfusion in surgery patients. Its primary products also comprise SEPO, a recombinant human erythropoietin for anemia associated with CKD and chemotherapy; Byetta/Bydureon, an exenatide injection to improve glycemic control in adults with type-2 diabetes mellitus; and Qiming Keli for retinopathy caused by type-2 diabetes. In addition, the company offers Ruisiyi to treat advanced breast cancer; Wanwei for treating vomiting caused by cytotoxic chemotherapy; and Intefen to treat lymphatic or hematopoietic malignancies and viral infections. Further, it provides Inleusin for renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis; Etanercept for moderate to severe rheumatoid arthritis and plaque psoriasis, and active ankylosing spondylitis; and Sparin for prophylaxis and vein thrombosis, and to prevent clotting during hemodialysis. Additionally, the company offers Mandi for male-pattern alopecia and alopecia areata; Aiyishu for iron-deficiency anemia; Disu to prevent and treat chronic bronchitis, colds, and asthma; Jiannipai to prevent acute rejection after renal transplantation; and Humulin for diabetes, as well as contract development and manufacturing, trading, project management and consultation, and technology services. The company markets its products through in-house sales and marketing team, as well as distributors and third-party promoters. 3SBio Inc. was incorporated in 2006 and is headquartered in Shenyang, the People's Republic of China.